Global Alagille Syndrome Market was valued US$ 385.13 Mn in 2022 and is expected to reach US$ 583.71 Mn by 2029, at a CAGR of 6.12% during a forecast period.Alagille Syndrome Market Overview
Alagille syndrome is a genetic disorder affecting body parts like liver, heart, etc. People with Alagille syndrome have less number of bile ducts inside the liver. Alagille syndrome is an exceptional autosomal leading genetic disorder that affects many organ systems of the body usually in the skeleton, liver, eyes, kidneys, and heart. Alagille syndrome is initiated by either change in the JAG1 gene or deletion in gene material on chromosome 20 that contains the JAG1 genetic factor. These proteins are essential for Notch signalling between neighbouring cells throughout embryonic development and error in genetic factor results in abnormalities in the heart, bile ducts, certain facial features, and spinal column.To know about the Research Methodology:- Request Free Sample Report The report study has analyzed the revenue impact of the COVID-19 pandemic on the sales revenue of the market leader, market followers, and market disrupters in the report, and the same is reflected in our analysis. As per the US Department of Health and Human Services statistics published, an expected annual prevalence of Alagille syndrome globally is 1 in 70000 newborns. Introduction of new drugs for Alagille syndrome treatment and advanced healthcare infrastructure is driving the growth of Alagille syndrome market. The MMR report covers all the trends and technologies playing major role in the growth of the Alagille syndrome market over the period 2022-2029. It highlights the opportunities, drivers, restraints, and challenges expected to influence the market growth throughout the forecast period.
Market Segment Analysis
Also, the MMR report will provide an accurate prediction of the contribution of various segments to the growth of the Alagille syndrome market size. By treatment, medication segment of Alagille syndrome is expected to grow at the highest CAGR of xx.78% and is expected to reach a value of US$ xx Mn. by 2029. Medications may be given to upsurge bile flow and lessen itching. Liver transplantation only needs to be considered for Alagille syndrome patients of small-group. It may be essential if there is a severe liver disease affecting cirrhosis or there are symptoms which can’t be precise in other ways. Liver transplantation for kids with Alagille syndrome can be further complex than other liver transplants since kids with Alagille syndrome may also have problems affecting the kidneys or heart.Regional Analysis
North America Alagille syndrome market was valued US$ xx Mn. in 2022 and is expected to reach a value of US$ xx Mn. by 2029, with a CAGR of xx.20% during the forecast period. This is attributed to the growing prevalence of rare genomic disease and well-developed healthcare industry. Along with the project of Global Genes, genetic and rare diseases affect 1 in 10 people in the U.S. However, Europe stood the second largest in the Alagille syndrome market owing to mounting prevalence of several liver diseases. In England, as per the Public Health, nearly 11,597 numbers of people died with an essential cause of liver disease in 2017. The report focuses on international major leading industry players of Alagille syndrome market providing information such as company profiles, revenue, and other related information. In 2022, Mirum Pharmaceuticals Company presented a phase-2 ICONIC clinical trial studies data at the Global Liver Congress-2022 for maralixibat for the Alagille syndrome treatment. The trial has recognized the well-tolerated dose with no thoughtful adverse events along with durable developments in serum bile acids and itch severity in children with Alagille syndrome. The objective of the report is to present a comprehensive analysis of the Global Alagille Syndrome Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Alagille Syndrome Market dynamics, structure by analyzing the market segments and projects the Global Alagille Syndrome Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Alagille Syndrome Market make the report investor’s guide.Alagille Syndrome Market Scope: Inquire before buying
Alagille Syndrome Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 385.13 Mn. Forecast Period 2023 to 2029 CAGR: 6.12% Market Size in 2029: US $ 583.71 Mn. Segments Covered: by Treatment Medication Surgery Liver Transplantation Kidney Surgery Others by Drugs Ursodeoxycholic Acid Cholestyramine Rifampin Naltrexone Others by Diagnosis Blood Test Urinalysis Others by End Users Hospitals Homecare Specialty Clinics Endocrinologists Others Alagille Syndrome Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina and Rest of South America)Alagille Syndrome Market Key Players are:
1. Albireo Pharma, Inc 2. Mirum Pharmaceuticals 3. Teva Pharmaceutical Industries Ltd 4. Zydus Cadila 5. ALLERGAN 6. Endo Pharmaceuticals Inc 7. ANI Pharmaceuticals, Inc 8. Mylan N.V. 9. Glenmark Pharmaceuticals Ltd 10.Amneal Pharmaceuticals LLC 11.Epic Pharma, LLC 12.Lannett 13.Fresenius Kabi AG 14.Lannett 15.Novartis AG 16.Pfizer, Inc 17.Lupin 18.Hikma Pharmaceuticals PLC 19.Akorn 20.Bioarray S.L. 21.Takeda Pharmaceutical Company Limited. 22.Astrazeneca 23.GlaxoSmithKline plc Frequently Asked Questions: 1. Which region has the largest share in Global Alagille Syndrome Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Alagille Syndrome Market? Ans: The Global Alagille Syndrome Market is growing at a CAGR of 6.12% during forecasting period 2023-2029. 3. What is scope of the Global Alagille Syndrome market report? Ans: Global Alagille Syndrome Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Alagille Syndrome market? Ans: The important key players in the Global Alagille Syndrome Market are – Albireo Pharma, Inc, Mirum Pharmaceuticals, Teva Pharmaceutical Industries Ltd, Zydus Cadila, ALLERGAN, Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett, Fresenius Kabi AG, Lannett, Novartis AG, Pfizer, Inc, Lupin, Hikma Pharmaceuticals PLC, Akorn, Bioarray S.L., Takeda Pharmaceutical Company Limited., Astrazeneca, and GlaxoSmithKline plc 5. What is the study period of this market? Ans: The Global Alagille Syndrome Market is studied from 2022 to 2029.
Global Alagille Syndrome Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Alagille Syndrome Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Alagille Syndrome Market Analysis and Forecast 6.1. Alagille Syndrome Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Alagille Syndrome Market Analysis and Forecast, By Drugs 7.1. Introduction and Definition 7.2. Key Findings 7.3. Alagille Syndrome Market Value Share Analysis, By Drugs 7.4. Alagille Syndrome Market Size (US$ Bn) Forecast, By Drugs 7.5. Alagille Syndrome Market Analysis, By Drugs 7.6. Alagille Syndrome Market Attractiveness Analysis, By Drugs 8. Global Alagille Syndrome Market Analysis and Forecast, By Diagnosis 8.1. Introduction and Definition 8.2. Key Findings 8.3. Alagille Syndrome Market Value Share Analysis, By Diagnosis 8.4. Alagille Syndrome Market Size (US$ Bn) Forecast, By Diagnosis 8.5. Alagille Syndrome Market Analysis, By Diagnosis 8.6. Alagille Syndrome Market Attractiveness Analysis, By Diagnosis 9. Global Alagille Syndrome Market Analysis and Forecast, By Treatment 9.1. Introduction and Definition 9.2. Key Findings 9.3. Alagille Syndrome Market Value Share Analysis, By Treatment 9.4. Alagille Syndrome Market Size (US$ Bn) Forecast, By Treatment 9.5. Alagille Syndrome Market Analysis, By Treatment 9.6. Alagille Syndrome Market Attractiveness Analysis, By Treatment 10. Global Alagille Syndrome Market Analysis and Forecast, By End Users 10.1. Introduction and Definition 10.2. Key Findings 10.3. Alagille Syndrome Market Value Share Analysis, By End Users 10.4. Alagille Syndrome Market Size (US$ Bn) Forecast, By End Users 10.5. Alagille Syndrome Market Analysis, By End Users 10.6. Alagille Syndrome Market Attractiveness Analysis, By End Users 11. Global Alagille Syndrome Market Analysis, by Region 11.1. Alagille Syndrome Market Value Share Analysis, by Region 11.2. Alagille Syndrome Market Size (US$ Bn) Forecast, by Region 11.3. Alagille Syndrome Market Attractiveness Analysis, by Region 12. North America Alagille Syndrome Market Analysis 12.1. Key Findings 12.2. North America Alagille Syndrome Market Overview 12.3. North America Alagille Syndrome Market Value Share Analysis, By Drugs 12.4. North America Alagille Syndrome Market Forecast, By Drugs 12.4.1. Ursodeoxycholic Acid 12.4.2. Cholestyramine 12.4.3. Rifampin 12.4.4. Naltrexone 12.4.5. Others 12.5. North America Alagille Syndrome Market Value Share Analysis, By Diagnosis 12.6. North America Alagille Syndrome Market Forecast, By Diagnosis 12.6.1. Blood Test 12.6.2. Urinalysis 12.6.3. Others 12.7. North America Alagille Syndrome Market Value Share Analysis, By Treatment 12.8. North America Alagille Syndrome Market Forecast, By Treatment 12.8.1. Medication 12.8.2. Surgery 12.8.2.1. Liver Transplantation 12.8.2.2. Kidney Surgery 12.8.2.3. Others 12.9. North America Alagille Syndrome Market Value Share Analysis, By End Users 12.10. North America Alagille Syndrome Market Forecast, By End Users 12.10.1. Hospitals 12.10.2. Homecare 12.10.3. Specialty Clinics 12.10.4. Endocrinologists 12.10.5. Others 12.11. North America Alagille Syndrome Market Value Share Analysis, by Country 12.12. North America Alagille Syndrome Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Alagille Syndrome Market Analysis, by Country 12.14. U.S. Alagille Syndrome Market Forecast, By Drugs 12.14.1. Ursodeoxycholic Acid 12.14.2. Cholestyramine 12.14.3. Rifampin 12.14.4. Naltrexone 12.14.5. Others 12.15. U.S. Alagille Syndrome Market Forecast, By Diagnosis 12.15.1. Blood Test 12.15.2. Urinalysis 12.15.3. Others 12.16. U.S. Alagille Syndrome Market Forecast, By Treatment 12.16.1. Medication 12.16.2. Surgery 12.16.2.1. Liver Transplantation 12.16.2.2. Kidney Surgery 12.16.2.3. Others 12.17. U.S. Alagille Syndrome Market Forecast, By End Users 12.17.1. Hospitals 12.17.2. Homecare 12.17.3. Specialty Clinics 12.17.4. Endocrinologists 12.17.5. Others 12.18. Canada Alagille Syndrome Market Forecast, By Drugs 12.18.1. Ursodeoxycholic Acid 12.18.2. Cholestyramine 12.18.3. Rifampin 12.18.4. Naltrexone 12.18.5. Others 12.19. Canada Alagille Syndrome Market Forecast, By Diagnosis 12.19.1. Blood Test 12.19.2. Urinalysis 12.19.3. Others 12.20. Canada Alagille Syndrome Market Forecast, By Treatment 12.20.1. Medication 12.20.2. Surgery 12.20.2.1. Liver Transplantation 12.20.2.2. Kidney Surgery 12.20.2.3. Others 12.21. Canada Alagille Syndrome Market Forecast, By End Users 12.21.1. Hospitals 12.21.2. Homecare 12.21.3. Specialty Clinics 12.21.4. Endocrinologists 12.21.5. Others 12.22. North America Alagille Syndrome Market Attractiveness Analysis 12.22.1. By Drugs 12.22.2. By Diagnosis 12.22.3. By Treatment 12.22.4. By End Users 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Alagille Syndrome Market Analysis 13.1. Key Findings 13.2. Europe Alagille Syndrome Market Overview 13.3. Europe Alagille Syndrome Market Value Share Analysis, By Drugs 13.4. Europe Alagille Syndrome Market Forecast, By Drugs 13.4.1. Ursodeoxycholic Acid 13.4.2. Cholestyramine 13.4.3. Rifampin 13.4.4. Naltrexone 13.4.5. Others 13.5. Europe Alagille Syndrome Market Value Share Analysis, By Diagnosis 13.6. Europe Alagille Syndrome Market Forecast, By Diagnosis 13.6.1. Blood Test 13.6.2. Urinalysis 13.6.3. Others 13.7. Europe Alagille Syndrome Market Value Share Analysis, By Treatment 13.8. Europe Alagille Syndrome Market Forecast, By Treatment 13.8.1. Medication 13.8.2. Surgery 13.8.2.1. Liver Transplantation 13.8.2.2. Kidney Surgery 13.8.2.3. Others 13.9. Europe Alagille Syndrome Market Value Share Analysis, By End Users 13.10. Europe Alagille Syndrome Market Forecast, By End Users 13.10.1. Hospitals 13.10.2. Homecare 13.10.3. Specialty Clinics 13.10.4. Endocrinologists 13.10.5. Others 13.11. Europe Alagille Syndrome Market Value Share Analysis, by Country 13.12. Europe Alagille Syndrome Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Alagille Syndrome Market Analysis, by Country 13.14. Germany Alagille Syndrome Market Forecast, By Drugs 13.14.1. Ursodeoxycholic Acid 13.14.2. Cholestyramine 13.14.3. Rifampin 13.14.4. Naltrexone 13.14.5. Others 13.15. Germany Alagille Syndrome Market Forecast, By Diagnosis 13.15.1. Blood Test 13.15.2. Urinalysis 13.15.3. Others 13.16. Germany Alagille Syndrome Market Forecast, By Treatment 13.16.1. Medication 13.16.2. Surgery 13.16.2.1. Liver Transplantation 13.16.2.2. Kidney Surgery 13.16.2.3. Others 13.17. Germany Alagille Syndrome Market Forecast, By End Users 13.17.1. Hospitals 13.17.2. Homecare 13.17.3. Specialty Clinics 13.17.4. Endocrinologists 13.17.5. Others 13.18. U.K. Alagille Syndrome Market Forecast, By Drugs 13.18.1. Ursodeoxycholic Acid 13.18.2. Cholestyramine 13.18.3. Rifampin 13.18.4. Naltrexone 13.18.5. Others 13.19. U.K. Alagille Syndrome Market Forecast, By Diagnosis 13.19.1. Blood Test 13.19.2. Urinalysis 13.19.3. Others 13.20. U.K. Alagille Syndrome Market Forecast, By Treatment 13.20.1. Medication 13.20.2. Surgery 13.20.2.1. Liver Transplantation 13.20.2.2. Kidney Surgery 13.20.2.3. Others 13.21. U.K. Alagille Syndrome Market Forecast, By End Users 13.21.1. Hospitals 13.21.2. Homecare 13.21.3. Specialty Clinics 13.21.4. Endocrinologists 13.21.5. Others 13.22. France Alagille Syndrome Market Forecast, By Drugs 13.22.1. Ursodeoxycholic Acid 13.22.2. Cholestyramine 13.22.3. Rifampin 13.22.4. Naltrexone 13.22.5. Others 13.23. France Alagille Syndrome Market Forecast, By Diagnosis 13.23.1. Blood Test 13.23.2. Urinalysis 13.23.3. Others 13.24. France Alagille Syndrome Market Forecast, By Treatment 13.24.1. Medication 13.24.2. Surgery 13.24.2.1. Liver Transplantation 13.24.2.2. Kidney Surgery 13.24.2.3. Others 13.25. France Alagille Syndrome Market Forecast, By End Users 13.25.1. Hospitals 13.25.2. Homecare 13.25.3. Specialty Clinics 13.25.4. Endocrinologists 13.25.5. Others 13.26. Italy Alagille Syndrome Market Forecast, By Drugs 13.26.1. Ursodeoxycholic Acid 13.26.2. Cholestyramine 13.26.3. Rifampin 13.26.4. Naltrexone 13.26.5. Others 13.27. Italy Alagille Syndrome Market Forecast, By Diagnosis 13.27.1. Blood Test 13.27.2. Urinalysis 13.27.3. Others 13.28. Italy Alagille Syndrome Market Forecast, By Treatment 13.28.1. Medication 13.28.2. Surgery 13.28.2.1. Liver Transplantation 13.28.2.2. Kidney Surgery 13.28.2.3. Others 13.29. Italy Alagille Syndrome Market Forecast, By End Users 13.29.1. Hospitals 13.29.2. Homecare 13.29.3. Specialty Clinics 13.29.4. Endocrinologists 13.29.5. Others 13.30. Spain Alagille Syndrome Market Forecast, By Drugs 13.30.1. Ursodeoxycholic Acid 13.30.2. Cholestyramine 13.30.3. Rifampin 13.30.4. Naltrexone 13.30.5. Others 13.31. Spain Alagille Syndrome Market Forecast, By Diagnosis 13.31.1. Blood Test 13.31.2. Urinalysis 13.31.3. Others 13.32. Spain Alagille Syndrome Market Forecast, By Treatment 13.32.1. Medication 13.32.2. Surgery 13.32.2.1. Liver Transplantation 13.32.2.2. Kidney Surgery 13.32.2.3. Others 13.33. Spain Alagille Syndrome Market Forecast, By End Users 13.33.1. Hospitals 13.33.2. Homecare 13.33.3. Specialty Clinics 13.33.4. Endocrinologists 13.33.5. Others 13.34. Rest of Europe Alagille Syndrome Market Forecast, By Drugs 13.34.1. Ursodeoxycholic Acid 13.34.2. Cholestyramine 13.34.3. Rifampin 13.34.4. Naltrexone 13.34.5. Others 13.35. Rest of Europe Alagille Syndrome Market Forecast, By Diagnosis 13.35.1. Blood Test 13.35.2. Urinalysis 13.35.3. Others 13.36. Rest of Europe Alagille Syndrome Market Forecast, By Treatment 13.36.1. Medication 13.36.2. Surgery 13.36.2.1. Liver Transplantation 13.36.2.2. Kidney Surgery 13.36.2.3. Others 13.37. Rest Of Europe Alagille Syndrome Market Forecast, By End Users 13.37.1. Hospitals 13.37.2. Homecare 13.37.3. Specialty Clinics 13.37.4. Endocrinologists 13.37.5. Others 13.38. Europe Alagille Syndrome Market Attractiveness Analysis 13.38.1. By Drugs 13.38.2. By Diagnosis 13.38.3. By Treatment 13.38.4. By End Users 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Alagille Syndrome Market Analysis 14.1. Key Findings 14.2. Asia Pacific Alagille Syndrome Market Overview 14.3. Asia Pacific Alagille Syndrome Market Value Share Analysis, By Drugs 14.4. Asia Pacific Alagille Syndrome Market Forecast, By Drugs 14.4.1. Ursodeoxycholic Acid 14.4.2. Cholestyramine 14.4.3. Rifampin 14.4.4. Naltrexone 14.4.5. Others 14.5. Asia Pacific Alagille Syndrome Market Value Share Analysis, By Diagnosis 14.6. Asia Pacific Alagille Syndrome Market Forecast, By Diagnosis 14.6.1. Blood Test 14.6.2. Urinalysis 14.6.3. Others 14.7. Asia Pacific Alagille Syndrome Market Value Share Analysis, By Treatment 14.8. Asia Pacific Alagille Syndrome Market Forecast, By Treatment 14.8.1. Medication 14.8.2. Surgery 14.8.2.1. Liver Transplantation 14.8.2.2. Kidney Surgery 14.8.2.3. Others 14.9. Asia Pacific Alagille Syndrome Market Value Share Analysis, By End Users 14.10. Asia Pacific Alagille Syndrome Market Forecast, By End Users 14.10.1. Hospitals 14.10.2. Homecare 14.10.3. Specialty Clinics 14.10.4. Endocrinologists 14.10.5. Others 14.11. Asia Pacific Alagille Syndrome Market Value Share Analysis, by Country 14.12. Asia Pacific Alagille Syndrome Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Alagille Syndrome Market Analysis, by Country 14.14. China Alagille Syndrome Market Forecast, By Drugs 14.14.1. Ursodeoxycholic Acid 14.14.2. Cholestyramine 14.14.3. Rifampin 14.14.4. Naltrexone 14.14.5. Others 14.15. China Alagille Syndrome Market Forecast, By Diagnosis 14.15.1. Blood Test 14.15.2. Urinalysis 14.15.3. Others 14.16. China Alagille Syndrome Market Forecast, By Treatment 14.16.1. Medication 14.16.2. Surgery 14.16.2.1. Liver Transplantation 14.16.2.2. Kidney Surgery 14.16.2.3. Others 14.17. China Alagille Syndrome Market Forecast, By End Users 14.17.1. Hospitals 14.17.2. Homecare 14.17.3. Specialty Clinics 14.17.4. Endocrinologists 14.17.5. Others 14.18. India Alagille Syndrome Market Forecast, By Drugs 14.18.1. Ursodeoxycholic Acid 14.18.2. Cholestyramine 14.18.3. Rifampin 14.18.4. Naltrexone 14.18.5. Others 14.19. India Alagille Syndrome Market Forecast, By Diagnosis 14.19.1. Blood Test 14.19.2. Urinalysis 14.19.3. Others 14.20. India Alagille Syndrome Market Forecast, By Treatment 14.20.1. Medication 14.20.2. Surgery 14.20.2.1. Liver Transplantation 14.20.2.2. Kidney Surgery 14.20.2.3. Others 14.21. India Alagille Syndrome Market Forecast, By End Users 14.21.1. Hospitals 14.21.2. Homecare 14.21.3. Specialty Clinics 14.21.4. Endocrinologists 14.21.5. Others 14.22. Japan Alagille Syndrome Market Forecast, By Drugs 14.22.1. Ursodeoxycholic Acid 14.22.2. Cholestyramine 14.22.3. Rifampin 14.22.4. Naltrexone 14.22.5. Others 14.23. Japan Alagille Syndrome Market Forecast, By Diagnosis 14.23.1. Blood Test 14.23.2. Urinalysis 14.23.3. Others 14.24. Japan Alagille Syndrome Market Forecast, By Treatment 14.24.1. Medication 14.24.2. Surgery 14.24.2.1. Liver Transplantation 14.24.2.2. Kidney Surgery 14.24.2.3. Others 14.25. Japan Alagille Syndrome Market Forecast, By End Users 14.25.1. Hospitals 14.25.2. Homecare 14.25.3. Specialty Clinics 14.25.4. Endocrinologists 14.25.5. Others 14.26. ASEAN Alagille Syndrome Market Forecast, By Drugs 14.26.1. Ursodeoxycholic Acid 14.26.2. Cholestyramine 14.26.3. Rifampin 14.26.4. Naltrexone 14.26.5. Others 14.27. ASEAN Alagille Syndrome Market Forecast, By Diagnosis 14.27.1. Blood Test 14.27.2. Urinalysis 14.27.3. Others 14.28. ASEAN Alagille Syndrome Market Forecast, By Treatment 14.28.1. Medication 14.28.2. Surgery 14.28.2.1. Liver Transplantation 14.28.2.2. Kidney Surgery 14.28.2.3. Others 14.29. ASEAN Alagille Syndrome Market Forecast, By End Users 14.29.1. Hospitals 14.29.2. Homecare 14.29.3. Specialty Clinics 14.29.4. Endocrinologists 14.29.5. Others 14.30. Rest of Asia Pacific Alagille Syndrome Market Forecast, By Drugs 14.30.1. Ursodeoxycholic Acid 14.30.2. Cholestyramine 14.30.3. Rifampin 14.30.4. Naltrexone 14.30.5. Others 14.31. Rest of Asia Pacific Alagille Syndrome Market Forecast, By Diagnosis 14.31.1. Blood Test 14.31.2. Urinalysis 14.31.3. Others 14.32. Rest of Asia Pacific Alagille Syndrome Market Forecast, By Treatment 14.32.1. Medication 14.32.2. Surgery 14.32.2.1. Liver Transplantation 14.32.2.2. Kidney Surgery 14.32.2.3. Others 14.33. Rest of Asia Pacific Alagille Syndrome Market Forecast, By End Users 14.33.1. Hospitals 14.33.2. Homecare 14.33.3. Specialty Clinics 14.33.4. Endocrinologists 14.33.5. Others 14.34. Asia Pacific Alagille Syndrome Market Attractiveness Analysis 14.34.1. By Drugs 14.34.2. By Diagnosis 14.34.3. By Treatment 14.34.4. By End Users 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Alagille Syndrome Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Alagille Syndrome Market Overview 15.3. Middle East & Africa Alagille Syndrome Market Value Share Analysis, By Drugs 15.4. Middle East & Africa Alagille Syndrome Market Forecast, By Drugs 15.4.1. Ursodeoxycholic Acid 15.4.2. Cholestyramine 15.4.3. Rifampin 15.4.4. Naltrexone 15.4.5. Others 15.5. Middle East & Africa Alagille Syndrome Market Value Share Analysis, By Diagnosis 15.6. Middle East & Africa Alagille Syndrome Market Forecast, By Diagnosis 15.6.1. Blood Test 15.6.2. Urinalysis 15.6.3. Others 15.7. Middle East & Africa Alagille Syndrome Market Value Share Analysis, By Treatment 15.8. Middle East & Africa Alagille Syndrome Market Forecast, By Treatment 15.8.1. Medication 15.8.2. Surgery 15.8.2.1. Liver Transplantation 15.8.2.2. Kidney Surgery 15.8.2.3. Others 15.9. Middle East & Africa Alagille Syndrome Market Value Share Analysis, By End Users 15.10. Middle East & Africa Alagille Syndrome Market Forecast, By End Users 15.10.1. Hospitals 15.10.2. Homecare 15.10.3. Specialty Clinics 15.10.4. Endocrinologists 15.10.5. Others 15.11. Middle East & Africa Alagille Syndrome Market Value Share Analysis, by Country 15.12. Middle East & Africa Alagille Syndrome Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Alagille Syndrome Market Analysis, by Country 15.14. GCC Alagille Syndrome Market Forecast, By Drugs 15.14.1. Ursodeoxycholic Acid 15.14.2. Cholestyramine 15.14.3. Rifampin 15.14.4. Naltrexone 15.14.5. Others 15.15. GCC Alagille Syndrome Market Forecast, By Diagnosis 15.15.1. Blood Test 15.15.2. Urinalysis 15.15.3. Others 15.16. GCC Alagille Syndrome Market Forecast, By Treatment 15.16.1. Medication 15.16.2. Surgery 15.16.2.1. Liver Transplantation 15.16.2.2. Kidney Surgery 15.16.2.3. Others 15.17. GCC Alagille Syndrome Market Forecast, By End Users 15.17.1. Hospitals 15.17.2. Homecare 15.17.3. Specialty Clinics 15.17.4. Endocrinologists 15.17.5. Others 15.18. South Africa Alagille Syndrome Market Forecast, By Drugs 15.18.1. Ursodeoxycholic Acid 15.18.2. Cholestyramine 15.18.3. Rifampin 15.18.4. Naltrexone 15.18.5. Others 15.19. South Africa Alagille Syndrome Market Forecast, By Diagnosis 15.19.1. Blood Test 15.19.2. Urinalysis 15.19.3. Others 15.20. South Africa Alagille Syndrome Market Forecast, By Treatment 15.20.1. Medication 15.20.2. Surgery 15.20.2.1. Liver Transplantation 15.20.2.2. Kidney Surgery 15.20.2.3. Others 15.21. South Africa Alagille Syndrome Market Forecast, By End Users 15.21.1. Hospitals 15.21.2. Homecare 15.21.3. Specialty Clinics 15.21.4. Endocrinologists 15.21.5. Others 15.22. Rest of Middle East & Africa Alagille Syndrome Market Forecast, By Drugs 15.22.1. Ursodeoxycholic Acid 15.22.2. Cholestyramine 15.22.3. Rifampin 15.22.4. Naltrexone 15.22.5. Others 15.23. Rest of Middle East & Africa Alagille Syndrome Market Forecast, By Diagnosis 15.23.1. Blood Test 15.23.2. Urinalysis 15.23.3. Others 15.24. Rest of Middle East & Africa Alagille Syndrome Market Forecast, By Treatment 15.24.1. Medication 15.24.2. Surgery 15.24.2.1. Liver Transplantation 15.24.2.2. Kidney Surgery 15.24.2.3. Others 15.25. Rest of Middle East & Africa Alagille Syndrome Market Forecast, By End Users 15.25.1. Hospitals 15.25.2. Homecare 15.25.3. Specialty Clinics 15.25.4. Endocrinologists 15.25.5. Others 15.26. Middle East & Africa Alagille Syndrome Market Attractiveness Analysis 15.26.1. By Drugs 15.26.2. By Diagnosis 15.26.3. By Treatment 15.26.4. By End Users 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Alagille Syndrome Market Analysis 16.1. Key Findings 16.2. South America Alagille Syndrome Market Overview 16.3. South America Alagille Syndrome Market Value Share Analysis, By Drugs 16.4. South America Alagille Syndrome Market Forecast, By Drugs 16.4.1. Ursodeoxycholic Acid 16.4.2. Cholestyramine 16.4.3. Rifampin 16.4.4. Naltrexone 16.4.5. Others 16.5. South America Alagille Syndrome Market Value Share Analysis, By Diagnosis 16.6. South America Alagille Syndrome Market Forecast, By Diagnosis 16.6.1. Blood Test 16.6.2. Urinalysis 16.6.3. Others 16.7. South America Alagille Syndrome Market Value Share Analysis, By Treatment 16.8. South America Alagille Syndrome Market Forecast, By Treatment 16.8.1. Medication 16.8.2. Surgery 16.8.2.1. Liver Transplantation 16.8.2.2. Kidney Surgery 16.8.2.3. Others 16.9. South America Alagille Syndrome Market Value Share Analysis, By End Users 16.10. South America Alagille Syndrome Market Forecast, By End Users 16.10.1. Hospitals 16.10.2. Homecare 16.10.3. Specialty Clinics 16.10.4. Endocrinologists 16.10.5. Others 16.11. South America Alagille Syndrome Market Value Share Analysis, by Country 16.12. South America Alagille Syndrome Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Alagille Syndrome Market Analysis, by Country 16.14. Brazil Alagille Syndrome Market Forecast, By Drugs 16.14.1. Ursodeoxycholic Acid 16.14.2. Cholestyramine 16.14.3. Rifampin 16.14.4. Naltrexone 16.14.5. Others 16.15. Brazil Alagille Syndrome Market Forecast, By Diagnosis 16.15.1. Blood Test 16.15.2. Urinalysis 16.15.3. Others 16.16. Brazil Alagille Syndrome Market Forecast, By Treatment 16.16.1. Medication 16.16.2. Surgery 16.16.2.1. Liver Transplantation 16.16.2.2. Kidney Surgery 16.16.2.3. Others 16.17. Brazil Alagille Syndrome Market Forecast, By End Users 16.17.1. Hospitals 16.17.2. Homecare 16.17.3. Specialty Clinics 16.17.4. Endocrinologists 16.17.5. Others 16.18. Mexico Alagille Syndrome Market Forecast, By Drugs 16.18.1. Ursodeoxycholic Acid 16.18.2. Cholestyramine 16.18.3. Rifampin 16.18.4. Naltrexone 16.18.5. Others 16.19. Mexico Alagille Syndrome Market Forecast, By Diagnosis 16.19.1. Blood Test 16.19.2. Urinalysis 16.19.3. Others 16.20. Mexico Alagille Syndrome Market Forecast, By Treatment 16.20.1. Medication 16.20.2. Surgery 16.20.2.1. Liver Transplantation 16.20.2.2. Kidney Surgery 16.20.2.3. Others 16.21. Mexico Alagille Syndrome Market Forecast, By End Users 16.21.1. Hospitals 16.21.2. Homecare 16.21.3. Specialty Clinics 16.21.4. Endocrinologists 16.21.5. Others 16.22. Rest of South America Alagille Syndrome Market Forecast, By Drugs 16.22.1. Ursodeoxycholic Acid 16.22.2. Cholestyramine 16.22.3. Rifampin 16.22.4. Naltrexone 16.22.5. Others 16.23. Rest of South America Alagille Syndrome Market Forecast, By Diagnosis 16.23.1. Blood Test 16.23.2. Urinalysis 16.23.3. Others 16.24. Rest of South America Alagille Syndrome Market Forecast, By Treatment 16.24.1. Medication 16.24.2. Surgery 16.24.2.1. Liver Transplantation 16.24.2.2. Kidney Surgery 16.24.2.3. Others 16.25. Rest of South America Alagille Syndrome Market Forecast, By End Users 16.25.1. Hospitals 16.25.2. Homecare 16.25.3. Specialty Clinics 16.25.4. Endocrinologists 16.25.5. Others 16.26. South America Alagille Syndrome Market Attractiveness Analysis 16.26.1. By Drugs 16.26.2. By Diagnosis 16.26.3. By Treatment 16.26.4. By End Users 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Albireo Pharma, Inc 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Development Footprint 17.3.2. Mirum Pharmaceuticals 17.3.3. Teva Pharmaceutical Industries Ltd 17.3.4. Zydus Cadila 17.3.5. ALLERGAN 17.3.6. Endo Pharmaceuticals Inc 17.3.7. ANI Pharmaceuticals, Inc 17.3.8. Mylan N.V. 17.3.9. Glenmark Pharmaceuticals Ltd 17.3.10. Amneal Pharmaceuticals LLC 17.3.11. Epic Pharma, LLC 17.3.12. Lannett 17.3.13. Fresenius Kabi AG 17.3.14. Lannett 17.3.15. Novartis AG 17.3.16. Pfizer, Inc 17.3.17. Lupin 17.3.18. Hikma Pharmaceuticals PLC 17.3.19. Akorn 17.3.20. Bioarray S.L. 17.3.21. Takeda Pharmaceutical Company Limited. 17.3.22. Astrazeneca 17.3.23. GlaxoSmithKline plc 18. Market Insights